Adrenergic beta-Antagonists

"Adrenergic beta-Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety.

Descriptor ID	D000319
MeSH Number(s)	D27.505.519.625.050.200.200 D27.505.696.577.050.200.200
Concept/Terms	Adrenergic beta-Antagonists Adrenergic beta-Antagonists Adrenergic beta Antagonists beta-Antagonists, Adrenergic beta-Adrenergic Receptor Blockaders Blockaders, beta-Adrenergic Receptor Receptor Blockaders, beta-Adrenergic beta Adrenergic Receptor Blockaders beta-Adrenergic Blockers Blockers, beta-Adrenergic beta Adrenergic Blockers beta-Blockers, Adrenergic Adrenergic beta-Blockers beta Blockers, Adrenergic Adrenergic beta-Receptor Blockaders Adrenergic beta Receptor Blockaders Blockaders, Adrenergic beta-Receptor beta-Receptor Blockaders, Adrenergic beta-Adrenergic Blocking Agents Agents, beta-Adrenergic Blocking Blocking Agents, beta-Adrenergic beta Adrenergic Blocking Agents

Below are MeSH descriptors whose meaning is more general than "Adrenergic beta-Antagonists".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Molecular Mechanisms of Pharmacological Action [D27.505.519]
Neurotransmitter Agents [D27.505.519.625]
Adrenergic Agents [D27.505.519.625.050]
Adrenergic Antagonists [D27.505.519.625.050.200]
Adrenergic beta-Antagonists [D27.505.519.625.050.200.200]
Physiological Effects of Drugs [D27.505.696]
Neurotransmitter Agents [D27.505.696.577]
Adrenergic Agents [D27.505.696.577.050]
Adrenergic Antagonists [D27.505.696.577.050.200]
Adrenergic beta-Antagonists [D27.505.696.577.050.200.200]

Below are MeSH descriptors whose meaning is related to "Adrenergic beta-Antagonists".

Below are MeSH descriptors whose meaning is more specific than "Adrenergic beta-Antagonists".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Adrenergic beta-Antagonists" by people in this website by year, and whether "Adrenergic beta-Antagonists" was a major or minor topic of these publications.

Bar chart showing 94 publications over 25 distinct years, with a maximum of 11 publications in 2010

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	1	0	1
1997	2	0	2
1998	1	1	2
1999	0	1	1
2002	2	1	3
2003	2	5	7
2004	3	3	6
2005	1	5	6
2006	0	3	3
2007	2	3	5
2008	2	4	6
2009	3	0	3
2010	5	6	11
2011	1	2	3
2012	2	1	3
2013	2	1	3
2014	2	2	4
2015	0	3	3
2016	1	3	4
2017	4	2	6
2018	1	2	3
2019	1	1	2
2020	1	2	3
2023	0	1	1
2024	0	3	3

Below are the most recent publications written about "Adrenergic beta-Antagonists" by people in Profiles.

Masri A, Choudhury L, Barriales-Villa R, Elliott P, Maron MS, Nassif ME, Oreziak A, Owens AT, Saberi S, Tower-Rader A, Rader F, Garcia-Pavia P, Olivotto I, Nagueh SF, Wang A, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Melloni C, Meng L, Wei J, Sherrid MV, Abraham TP. Standard-of-Care Medication Withdrawal in Patients With Obstructive Hypertrophic Cardiomyopathy Receiving Aficamten in FOREST-HCM. J Am Coll Cardiol. 2024 Nov 05; 84(19):1839-1849.

View in: PubMed
Schwann AN, Jaffe LM, Givertz MM, Wood KL, Engelman DT. Early Initiation of Guideline-Directed Medical Therapy for Heart Failure After Cardiac Surgery. Ann Thorac Surg. 2024 10; 118(4):792-800.

View in: PubMed
Goldfine CE, Troger A, Erickson TB, Chai PR. Beta-blocker and calcium-channel blocker toxicity: current evidence on evaluation and management. Eur Heart J Acute Cardiovasc Care. 2024 Feb 16; 13(2):247-253.

View in: PubMed
Ahsan MJ, Ahmad S, Dvalishvili M, Yousaf A, Sigurdsson G, Goldsweig AM. Effect of ?-Blocker Use on Long-Term Mortality in Takotsubo Cardiomyopathy: A Systematic Review and Meta-Analysis. Am J Cardiol. 2023 10 01; 204:168-170.

View in: PubMed
Bosch NA, Rucci JM, Massaro JM, Winter MR, Quinn EK, Chon KH, McManus DD, Walkey AJ. Comparative Effectiveness of Heart Rate Control Medications for the Treatment of Sepsis-Associated Atrial Fibrillation. Chest. 2021 04; 159(4):1452-1459.

View in: PubMed
Rowin EJ, Sridharan A, Madias C, Firely C, Koethe B, Link MS, Maron MS, Maron BJ. Prediction and Prevention of Sudden Death in Young Patients (<20 years) With Hypertrophic Cardiomyopathy. Am J Cardiol. 2020 08 01; 128:75-83.

View in: PubMed
Alowais SA, Hayes BD, Wilcox SR, Le J, Koehl JL, Fuh L. Heart rate outcomes with concomitant parenteral calcium channel blockers and beta blockers in rapid atrial fibrillation or flutter. Am J Emerg Med. 2021 06; 44:407-410.

View in: PubMed
Mercado-Lubo R, Yarzebski J, Lessard D, Gore J, Goldberg RJ. Changing Trends in the Landscape of Patients Hospitalized With Acute Myocardial Infarction (2001 to 2011) (from the Worcester Heart Attack Study). Am J Cardiol. 2020 03 01; 125(5):673-677.

View in: PubMed
Banerji D, Alvi RM, Afshar M, Tariq N, Rokicki A, Mulligan CP, Zhang L, Hassan MO, Awadalla M, Groarke JD, Neilan TG. Carvedilol Among Patients With Heart?Failure With a Cocaine-Use?Disorder. JACC Heart Fail. 2019 09; 7(9):771-778.

View in: PubMed
Zullo AR, Olean M, Berry SD, Lee Y, Tjia J, Steinman MA. Patient-Important Adverse Events of ?-blockers in Frail Older Adults after Acute Myocardial Infarction. J Gerontol A Biol Sci Med Sci. 2019 07 12; 74(8):1277-1281.

View in: PubMed

People

Explore

Similar Concepts

Top Journals